ImmunoGen Inc expected to post a loss of 25 cents a share - Earnings Preview

ImmunoGen

26/04/2023 15:34

* ImmunoGen Inc  IMGN.OQ   IMGN.O  is expected to show a
fall in
quarterly revenue when it reports  results on April 28. 
    * The Waltham Massachusetts-based  company is expected to
report 
a 46.2% decrease in revenue to $20.472 million from $38.08
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ImmunoGen Inc is
for a
loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$12​, above​ its last closing price of $4.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.29       -0.30      -0.23     Beat    22.5
 Sep. 30 2022  -0.26       -0.25      -0.31     Missed  -21.8
 Jun. 30 2022  -0.20       -0.21      -0.24     Missed  -13.2​
 Mar. 31 2022  -0.21       -0.21      -0.10     Beat    52.6
 ​​Dec.        -1.63       -1.71      -0.17     Beat    90
 31 2021                                                
 Sep. 30 2021  -0.18       -0.18      -0.18     Met     2.4​
 Jun. 30 2021  -0.18       -0.18      -0.15     Beat    17.7
 Mar. 31 2021  -0.19       -0.19      -0.17     Beat    9.3
 This summary was machine generated April 26 at 14:34 GMT.  All
figures in US dollars  unless otherwise stated